Skip to main content
Erschienen in: Virchows Archiv 3/2017

22.06.2017 | Original Article

Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma

verfasst von: Ben Davidson, Ellen Hellesylt, Arild Holth, Håvard Emil Danielsen, Tone Skeie-Jensen, Betina Katz

Erschienen in: Virchows Archiv | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to validate the diagnostic and clinical role of four protein products of genes previously found to be differentially expressed in uterine low-grade endometrial stromal sarcoma (LG-ESS) compared to uterine leiomyosarcoma (LMS). Protein expression by immunohistochemistry of transgelin (TGLN), neuron navigator-2 (NAV2), fatty acid binding protein-3 (FABP3), and cyclin D2 (CCND2) was analyzed in 305 uterine sarcomas (231 LMS, 74 LG-ESS). Expression was analyzed for association with clinicopathologic parameters and survival. TGLN (p < 0.001), NAV2 (p < 0.001), and FABP3 (p = 0.005) were overexpressed in LMS compared to LG-ESS, whereas nuclear CCND2 (p < 0.001) was overexpressed in LG-ESS. NAV2 expression was associated with shorter overall survival in patients with LMS (p = 0.037), whereas nuclear CCND2 expression in LG-ESS was significantly related to longer survival (p = 0.012) in univariate analysis. Nuclear CCND2 expression was an independent prognosticator in Cox multivariate analysis (p = 0.023). In conclusion, TGLN, FABP3, NAV2, and nuclear CCND2 aid in differentiating LG-ESS from LMS. NAV2 and CCND2 are novel candidate prognostic markers in LMS and LG-ESS, respectively.
Literatur
1.
Zurück zum Zitat Toro JR, Travis LB, Wu HJ et al (2006) Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer 119:2922–2930CrossRefPubMed Toro JR, Travis LB, Wu HJ et al (2006) Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer 119:2922–2930CrossRefPubMed
3.
Zurück zum Zitat Kurman RJ, Carcangiu ML, Herrington CS et al (2014) WHO classification of tumours of female reproductive organs. IARC, Lyon, France Kurman RJ, Carcangiu ML, Herrington CS et al (2014) WHO classification of tumours of female reproductive organs. IARC, Lyon, France
4.
Zurück zum Zitat Veras E, Zivanovic O, Jacks L et al (2011) “Low-grade leiomyosarcoma” and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas. Am J Surg Pathol 35:1626–1637CrossRefPubMed Veras E, Zivanovic O, Jacks L et al (2011) “Low-grade leiomyosarcoma” and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas. Am J Surg Pathol 35:1626–1637CrossRefPubMed
5.
Zurück zum Zitat Oliva E, Young RH, Amin MB et al (2002) An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 26:403–412CrossRefPubMed Oliva E, Young RH, Amin MB et al (2002) An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 26:403–412CrossRefPubMed
6.
Zurück zum Zitat Abeler VM, Nenodovic M (2011) Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol 30:236–243CrossRefPubMed Abeler VM, Nenodovic M (2011) Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol 30:236–243CrossRefPubMed
7.
Zurück zum Zitat Davidson B, Abeler VM, Hellesylt E et al (2013) Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. Gynecol Oncol 128:349–355CrossRefPubMed Davidson B, Abeler VM, Hellesylt E et al (2013) Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. Gynecol Oncol 128:349–355CrossRefPubMed
8.
Zurück zum Zitat Abeler VM, Røyne O, Thoresen S et al (2009) Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 54:355–364CrossRefPubMed Abeler VM, Røyne O, Thoresen S et al (2009) Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 54:355–364CrossRefPubMed
9.
Zurück zum Zitat Musgrove EA, Caldon CE, Barraclough J et al (2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11:558–572CrossRefPubMed Musgrove EA, Caldon CE, Barraclough J et al (2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11:558–572CrossRefPubMed
10.
Zurück zum Zitat Assinder SJ, Stanton JA, Prasad PD (2009) Transgelin: an actin-binding protein and tumour suppressor. Int J Biochem Cell Biol 41:482–486CrossRefPubMed Assinder SJ, Stanton JA, Prasad PD (2009) Transgelin: an actin-binding protein and tumour suppressor. Int J Biochem Cell Biol 41:482–486CrossRefPubMed
12.
Zurück zum Zitat McNeill EM, Klöckner-Bormann M, Roesler EC et al (2011) Nav2 hypomorphic mutant mice are ataxic and exhibit abnormalities in cerebellar development. Dev Biol 353:331–343CrossRefPubMedPubMedCentral McNeill EM, Klöckner-Bormann M, Roesler EC et al (2011) Nav2 hypomorphic mutant mice are ataxic and exhibit abnormalities in cerebellar development. Dev Biol 353:331–343CrossRefPubMedPubMedCentral
13.
14.
Zurück zum Zitat Cancer Genome Atlas Network (2012) Comprehensive molecular charactserization of human colon and rectal cancer. Nature 487:330–337CrossRef Cancer Genome Atlas Network (2012) Comprehensive molecular charactserization of human colon and rectal cancer. Nature 487:330–337CrossRef
15.
Zurück zum Zitat Robin YM, Penel N, Pérot G et al (2013) Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors. Mod Pathol 26:502–510CrossRefPubMed Robin YM, Penel N, Pérot G et al (2013) Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors. Mod Pathol 26:502–510CrossRefPubMed
16.
Zurück zum Zitat Tawfik O, Rao D, Nothnick WB et al (2014) Transgelin, a novel marker of smooth muscle differentiation, effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Int J Gynecol Obstet Reprod Med Res 1:26–31PubMedPubMedCentral Tawfik O, Rao D, Nothnick WB et al (2014) Transgelin, a novel marker of smooth muscle differentiation, effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Int J Gynecol Obstet Reprod Med Res 1:26–31PubMedPubMedCentral
17.
Zurück zum Zitat Hwang H, Matsuo K, Duncan K et al (2015) Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new. J Clin Pathol 68:710–717CrossRefPubMed Hwang H, Matsuo K, Duncan K et al (2015) Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new. J Clin Pathol 68:710–717CrossRefPubMed
18.
Zurück zum Zitat Tan F, Zhu H, Tao Y et al (2015) Neuron navigator 2 overexpression indicates poor prognosis of colorectal cancer and promotes invasion through the SSH1L/cofilin-1 pathway. J Exp Clin Cancer Res 34:117CrossRefPubMedPubMedCentral Tan F, Zhu H, Tao Y et al (2015) Neuron navigator 2 overexpression indicates poor prognosis of colorectal cancer and promotes invasion through the SSH1L/cofilin-1 pathway. J Exp Clin Cancer Res 34:117CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Tang Z, Shen Q, Xie H et al (2016) Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC). Oncotarget 7:46253–46262CrossRefPubMedPubMedCentral Tang Z, Shen Q, Xie H et al (2016) Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC). Oncotarget 7:46253–46262CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Takano Y, Kato Y, Masuda M et al (1999) Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol 189:194–200CrossRefPubMed Takano Y, Kato Y, Masuda M et al (1999) Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol 189:194–200CrossRefPubMed
21.
Zurück zum Zitat Rao D, Kimler BF, Nothnick WB et al (2015) Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers. Hum Pathol 46:876–883CrossRefPubMedPubMedCentral Rao D, Kimler BF, Nothnick WB et al (2015) Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers. Hum Pathol 46:876–883CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Lin Y, Buckhaults PJ, Lee JR et al (2009) Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer. Neoplasia 11:864–873CrossRefPubMedPubMedCentral Lin Y, Buckhaults PJ, Lee JR et al (2009) Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer. Neoplasia 11:864–873CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Zhou L, Zhang R, Zhang L et al (2013) Upregulation of transgelin is an independent factor predictive of poor prognosis in patients with advanced pancreatic cancer. Cancer Sci 104:423–430CrossRefPubMed Zhou L, Zhang R, Zhang L et al (2013) Upregulation of transgelin is an independent factor predictive of poor prognosis in patients with advanced pancreatic cancer. Cancer Sci 104:423–430CrossRefPubMed
24.
Zurück zum Zitat Zhao L, Wang H, Deng YJ et al (2009) Transgelin as a suppressor is associated with poor prognosis in colorectal carcinoma patients. Mod Pathol 22:786–796PubMed Zhao L, Wang H, Deng YJ et al (2009) Transgelin as a suppressor is associated with poor prognosis in colorectal carcinoma patients. Mod Pathol 22:786–796PubMed
25.
Zurück zum Zitat Pérot G, Mendiboure J, Brouste V et al (2014) Smooth muscle differentiation identifies two classes of poorly differentiated pleomorphic sarcomas with distinct outcome. Mod Pathol 27:840–850CrossRefPubMed Pérot G, Mendiboure J, Brouste V et al (2014) Smooth muscle differentiation identifies two classes of poorly differentiated pleomorphic sarcomas with distinct outcome. Mod Pathol 27:840–850CrossRefPubMed
26.
Zurück zum Zitat Davidson B, Kjæreng ML, Førsund M et al (2016) Progesterone receptor expression is an independent prognosticator in FIGO stage I uterine leiomyosarcoma. Am J Clin Pathol 145:449–458CrossRefPubMed Davidson B, Kjæreng ML, Førsund M et al (2016) Progesterone receptor expression is an independent prognosticator in FIGO stage I uterine leiomyosarcoma. Am J Clin Pathol 145:449–458CrossRefPubMed
Metadaten
Titel
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
verfasst von
Ben Davidson
Ellen Hellesylt
Arild Holth
Håvard Emil Danielsen
Tone Skeie-Jensen
Betina Katz
Publikationsdatum
22.06.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 3/2017
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-017-2172-5

Weitere Artikel der Ausgabe 3/2017

Virchows Archiv 3/2017 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …